The Role of Claudin-1 in Enhancing Pancreatic Cancer Aggressiveness and Drug Resistance via Metabolic Pathway Modulation
These findings indicate that the abnormal expression of claudin-1 promotes tumor progression and drug resistance through its interaction with aldo-keto reductase proteins, highlighting claudin-1 and aldo-keto reductase family proteins as potential biomarkers and therapeutic targets for pancreatic cancer.
Authors
- Daisuke Kyuno (ORCID: https://orcid.org/0000-0003-4672-535X)
- Yuna Nakamori (ORCID: https://orcid.org/0009-0007-2847-1022)
- Takumi Konno (ORCID: https://orcid.org/0000-0002-9339-3864)
- Yasutoshi Kimura (ORCID: https://orcid.org/0000-0002-7790-9250)
- Akira Takasawa (ORCID: https://orcid.org/0000-0002-3244-1199)
- Takashi Kojima (ORCID: https://orcid.org/0000-0002-6346-4588)
- Masafumi Imamura (ORCID: https://orcid.org/0000-0001-7669-7666)
- Kumi Takasawa (ORCID: https://orcid.org/0000-0001-6833-6211)
- Yusuke Ono (ORCID: https://orcid.org/0000-0003-3117-9720)
- Ryota Okumura (ORCID: https://orcid.org/0000-0002-1554-4081)
- Makoto Osanai (ORCID: https://orcid.org/0000-0003-1754-252X)
- Haruhiko Asano
- Kazufumi Magara (ORCID: https://orcid.org/0000-0002-4003-6011)
Institutions
- Sapporo Medical University (JP)
- Asahikawa Medical University (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-04-27
- DOI
- https://doi.org/10.3390/cancers17091469
- Citations
- 3
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Pancreas Research Foundation of Japan
- Japan Society for the Promotion of Science